Form 4: Keros Therapeutics Chief Medical Officer Receives 44,000 Restricted Stock Units
SEC Form 4 Filing
Keros Therapeutics' Chief Medical Officer, Yung H. Chyung, was granted 44,000 restricted stock units (RSUs) on February 18, 2025, which vest over a two-year period.
Summary
- On February 18, 2025, Yung H. Chyung, the Chief Medical Officer of Keros Therapeutics, Inc., received 44,000 shares of common stock in the form of restricted stock units (RSUs).
- These RSUs were granted at a price of $0 per share.
- The RSUs vest in three tranches: 33% on February 17, 2026, 34% on August 15, 2026, and the remaining 33% on February 16, 2027.
- Vesting is contingent upon the reporting person's continuous service with the company through each applicable vesting date.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral to slightly positive event.
Positives
- The RSU grant aligns the Chief Medical Officer's interests with the long-term success of Keros Therapeutics.
- The vesting schedule encourages continued service and commitment from the executive.
Risks
- The value of the RSUs is dependent on the future stock price of Keros Therapeutics.
- If the reporting person ceases continuous service before the vesting dates, they will forfeit the unvested RSUs.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs.
Industry Context
Granting stock-based compensation is a common practice in the biotechnology industry to attract, retain, and incentivize key executives.
Comparison to Industry Standards
- RSU grants are a standard form of executive compensation in the biotech industry, often used by companies like Amgen, Biogen, and Gilead Sciences.
- The vesting schedule is typical, aligning with industry norms for incentivizing long-term performance.
Stakeholder Impact
- Shareholders may view the RSU grant as a positive incentive for the Chief Medical Officer to drive long-term value.
- Employees may see this as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 02/18/2025 | Date of the RSU transaction. |
| 02/17/2026 | First vesting date for 33% of the RSUs. |
| 08/15/2026 | Second vesting date for 34% of the RSUs. |
| 02/16/2027 | Final vesting date for the remaining 33% of the RSUs. |
| 02/19/2025 | Date of the Form 4 filing. |
Keywords
Keros Therapeutics, Chief Medical Officer, Yung H. Chyung, restricted stock units, RSUs, Form 4, beneficial ownership, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.